drugset / Trial / NCT01581411

Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion

NCT01581411

Phase 1 Completed 1 enrolled Weill Medical College of Cornell University
NaSingle-groupOpen-labelTreatment

Summary

Central retinal vein occlusion (CRVO) is a common cause of vision loss, typically affecting individuals during the fifth through seventh decade of life. Eyes with severe CRVO have a poor visual prognosis because current treatments address only secondary complications of CRVO without treating its cause. Intra-ophthalmic artery injection of a small dose of t-PA (clot busting medicine), also called intra-ophthalmic artery thrombolysis, may reopen the central retinal vein-and address the cause of the disease- without exposing the subject to the risks of systemic thrombolysis. Our project aims to evaluate the safety and efficacy of intra-ophthalmic artery thrombolysis in subjects with CRVO.

Timeline

Start
2012-01
Primary completion
2015-11
Completion
2015-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Alteplase Protein / enzyme biologic 10 mg Other